Logo image of AQS.CA

Aequus Pharmaceuticals Inc (AQS.CA) Stock Fundamental Analysis

TSX-V:AQS - TSX Venture Exchange - CA0076361033 - Common Stock - Currency: CAD

0.005  0 (0%)

Fundamental Rating

0

Overall AQS gets a fundamental rating of 0 out of 10. We evaluated AQS against 34 industry peers in the Pharmaceuticals industry. AQS has a bad profitability rating. Also its financial health evaluation is rather negative. AQS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AQS has reported negative net income.
In the past year AQS has reported a negative cash flow from operations.
In the past 5 years AQS always reported negative net income.
AQS had a negative operating cash flow in each of the past 5 years.
AQS.CA Yearly Net Income VS EBIT VS OCF VS FCFAQS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

AQS's Return On Assets of -311.85% is on the low side compared to the rest of the industry. AQS is outperformed by 97.06% of its industry peers.
Industry RankSector Rank
ROA -311.85%
ROE N/A
ROIC N/A
ROA(3y)-168.11%
ROA(5y)-144.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQS.CA Yearly ROA, ROE, ROICAQS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

With a decent Gross Margin value of 53.46%, AQS is doing good in the industry, outperforming 79.41% of the companies in the same industry.
AQS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AQS.CA Yearly Profit, Operating, Gross MarginsAQS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

AQS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AQS has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, AQS has more shares outstanding
The debt/assets ratio for AQS is higher compared to a year ago.
AQS.CA Yearly Shares OutstandingAQS.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
AQS.CA Yearly Total Debt VS Total AssetsAQS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -67.10, we must say that AQS is in the distress zone and has some risk of bankruptcy.
AQS has a worse Altman-Z score (-67.10) than 94.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -67.1
ROIC/WACCN/A
WACC2.24%
AQS.CA Yearly LT Debt VS Equity VS FCFAQS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M -4M

2.3 Liquidity

AQS has a Current Ratio of 0.05. This is a bad value and indicates that AQS is not financially healthy enough and could expect problems in meeting its short term obligations.
AQS has a worse Current ratio (0.05) than 97.06% of its industry peers.
A Quick Ratio of 0.03 indicates that AQS may have some problems paying its short term obligations.
AQS has a worse Quick ratio (0.03) than 97.06% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.03
AQS.CA Yearly Current Assets VS Current LiabilitesAQS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.22% over the past year.
AQS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.63%.
AQS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.97% yearly.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.59%
Revenue 1Y (TTM)-29.63%
Revenue growth 3Y-53.85%
Revenue growth 5Y-28.97%
Sales Q2Q%1006.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AQS.CA Yearly Revenue VS EstimatesAQS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
AQS.CA Yearly EPS VS EstimatesAQS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AQS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQS.CA Price Earnings VS Forward Price EarningsAQS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQS.CA Per share dataAQS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AQS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Aequus Pharmaceuticals Inc

TSX-V:AQS (4/25/2025, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-24 2025-04-24
Earnings (Next)05-07 2025-05-07
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.68%
Ins Owner ChangeN/A
Market Cap663.15K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.6
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -311.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.46%
FCFM N/A
ROA(3y)-168.11%
ROA(5y)-144.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.03
Altman-Z -67.1
F-Score1
WACC2.24%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-29.63%
Revenue growth 3Y-53.85%
Revenue growth 5Y-28.97%
Sales Q2Q%1006.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.57%
OCF growth 3YN/A
OCF growth 5YN/A